Year: 2025
Type: article
Study design: Case Report
Abstract: Background: Diagnosis and treatment of systemic mastocytosis remain a challenge for clinicians. Disease symptoms vary, and close cooperation with other specialists is highly required. Despite the wider access to novel targeting molecules, there is still a place for conventional chemotherapy. Case report: A reported patient had advanced systemic mastocytosis, which failed the multikinase inhibitor — midostaurin, but responded promptly to 2-CdA with cytarabine. Conclusions: Avapritinib — a selective and potent KIT inhibitor was found to be effective as response maintenance.
Source: Hematology in Clinical Practice
DOI: 10.5603/hicp.100841
Authors: Karolina Chromik, Grzegorz Helbig
Institution: Medical University of Silesia
Language: English
Topic: Mast cells and histamine
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
OpenAlex ID: W4411026286